Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation
Glia · 2025-10 · 73 (10) · 1928-1950
DOI: 10.1002/glia.70044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Glia, online erschienen am 23.05.2025. Verfasst von Volker Siffrin. Beteiligte Einrichtung: Experimental and Clinical Research Center, Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Neuroglia, Multiple Sclerosis, Neuroinflammatory Diseases, Central Nervous System. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Gemeinnützige Hertie-Stiftung.
Abstract (Originalsprache)
Multiple sclerosis (MS) is the most common non‐infectious inflammatory CNS disease, characterized by progressive neurodegeneration and focal demyelinated lesions. Traditionally considered an autoimmune disease, MS is driven by the immune system's attack on CNS myelin, resulting in cumulative disability. However, conventional anti‐inflammatory treatments often fail to prevent progressive deterioration, particularly in the absence of overt inflammation, highlighting the need for a deeper understanding of its pathogenesis. Recent research has revealed a more complex disease mechanism involving both peripheral immune responses and intrinsic CNS factors, with glial cells playing a central role. Persistent inflammation in MS is associated with mixed active/inactive lesions dominated by microglia and astrocyte dysregulation. These glial populations exhibit maladaptive activation, contributing to failed remyelination and ongoing neurodegeneration. Transcriptomic and epigenomic alterations as well as aging further exacerbate glial dysfunction, creating a self‐perpetuating cycle of inflammation and damage. Emerging evidence suggests that the interplay between peripheral immune cells and glial populations and the potential dual‐use nature of molecular tools shared by the immune system and CNS disrupts homeostatic signaling, leading to a loss of tissue integrity. This review synthesizes findings on glial cell biology in MS, with a focus on microglia and astrocytes, while addressing their roles in demyelination, synapse loss, and neurodegeneration. The limitations of animal models, particularly EAE, in replicating the complexity of MS are also addressed. Finally, critical questions are outlined to guide future research into glial pathology and to identify novel therapeutic approaches targeting progressive MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Experimental and Clinical Research Center, Max-Delbrück-Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- Gemeinnützige Hertie-Stiftung
Zitieren
APA
Siffrin, V. (2025). Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation. Glia, 73(10), 1928-1950. https://doi.org/10.1002/glia.70044
Vancouver
Siffrin V. Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation. Glia. 2025;73(10):1928-1950. doi:10.1002/glia.70044
BibTeX
@article{Siffrin2025,
author = {Siffrin, Volker},
title = {Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation},
journal = {Glia},
year = {2025},
volume = {73},
number = {10},
pages = {1928--1950},
doi = {10.1002/glia.70044}
}
EUVIMED